N/A N=4 Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment of Post-Stroke Spasticity
Spasticity
Primary: Change From Baseline Contralesional Corticospinal Excitability — 67.88; -37.23 microVolts
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=109 Study Of GSK1358820 In Patients With Post-Stroke Upper Limb Spasticity
Post-Stroke Spasticity · Cerebrovascular Accident
Primary: Area Under the Curve (AUC) for the Change From Baseline in Modified Ashworth Scale (MAS) Wrist Score to the End of the DB Phase (Week 12) in the High-dose Groups…
Phase 3 N=468 BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity
Muscle Spasticity
Primary: Change From Baseline in Modified Ashworth Scale-Bohannon (MAS-B) Score of Ankle Plantar Flexors Using a 6-Point Scale — 4.1; 4.1; -0.81; -0.61 Scores on a Scale
Phase 4 N=60 SISTERS: Spasticity In Stroke Study - Randomized Study
Severe Spasticity
Primary: Change in Average Ashworth Scale (AS) in Affected Lower Extremities From Baseline to Month 6 — -0.99; -0.43 units on a scale — p=0.0140
Phase 4 N=42 Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression
Stroke · Upper Limb Spasticity
Primary: Time Between the Initial Injection and the Appearance of Reinjection Criteria as Evaluated by the Modified Ashworth Scale (MAS) and Spasticity Symptoms — 156; 32 days…
Phase 3 N=289 Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Post-stroke Spasticity of the Lower Limb
Primary: Change From Baseline in Ashworth Scale (AS) for Plantar Flexors at Week 4 — 2.8; 2.8; -0.4; -0.4 Units on a scale — p=0.777
Phase 3 N=243 Dysport® Adult Upper Limb Spasticity
Nervous System Disorders
Primary: Change From Baseline in MAS Score in the Primary Targeted Muscle Group (PTMG) — -0.3; -1.2; -1.4 units on a scale
Phase 3 N=317 Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke
Post-stroke Spasticity of the Upper Limb
Primary: Change From Baseline in Ashworth Scale (AS) Score of Primary Target Clinical Pattern — -0.9; -0.5 units on a scale — p=<0.001
Phase 3 N=120 Study of GSK1358820 In Patients With Post-Stroke Lower Limb Spasticity
Post-Stroke Spasticity · Cerebrovascular Accident
Primary: Area Under the Curve (AUC) for the Change From Baseline in Modified Ashworth Scale (MAS) Ankle Score to the End of the DB Phase (Week 12) — -8.513; -5.085 Score*week…
N/A N=31 Efficacy and Safety Study of Botulinum Neurotoxin A With Rehabilitation Versus Botulinum Neurotoxin A Alone in Treatment of Post-stroke Spasticity
Upper Limb Spasticity
Primary: The Maximum Change in Fugl-Meyer Upper Extremity Score From the Baseline Exam to Any Post Injection Visit in Each Treatment Arm. Comparison of the Difference Scores…
Phase 4 N=274 BOTOX® Economic Spasticity Trial (BEST)
Muscle Spasticity
Primary: Physician Assessment of Success, as Determined by Percentage of Patients Who Achieve Their Principal Active Functional Goal at Week 24 — 40.9; 33.3 Percentage of Patients
Phase 3 N=109 A Multicenter, Open-label, Single Dose Study of the Safety and Efficacy of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Focal Upper Limb Spasticity
Spasticity, Post-Stroke
Primary: Change From Baseline at Week 6 and Week 12 for Wrist Flexor Muscle Tone as Measured on the Modified Ashworth Scale (MAS) — -1.21; -1.33; -0.88; -1.12 scores on a scale…
Phase 3 N=345 Dysport® Adult Lower Limb Spasticity Follow-on Study
Post-stroke Spasticity · Spasticity Post-Traumatic Brain Injury
Primary: Assessment of the Long-Term Safety of Dysport® Through the Collection of Treatment Emergent Adverse Events (TEAEs) — 140; 97; 47; 21 participants
Phase 3 N=388 Dysport® Adult Lower Limb Spasticity Study
Leg Spasticity
Primary: Least Squares Mean Change From Baseline to Week 4 in the MAS Score in the Gastrocnemius-soleus Complex (GSC) (Knee Extended) — -0.6; -0.8; -0.5 units on a scale…
Phase 3 N=124 A Phase III Study to Evaluate the Efficacy and Safety of GSK1358820 in Subjects With Post-stroke Upper Limb Spasticity
Spasticity, Post-Stroke
Primary: Percentage of Participants Who Had Modified Ashworth Scale (MAS) Score Reduced at Least 1 From Baseline in the Elbow Flexors at Week 6 — 50.8; 68.9 Percentage of…
Phase 3 N=196 MEDITOXIN® Versus BOTOX® in the Treatment of Post-stroke Spasticity of the Upper Limb Spasticity
Spasticity
Primary: MAS(Modified Ashworth Scale) of Wrist Flexor — 2.41; 2.52; 1.02; 0.96 Scores on a MAS Scale — p=0.1347
Phase 3 N=170 A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Upper Limb Spasticity
Cerebrovascular Accident
Primary: Change From Baseline at Week 6 for Wrist Flexor Muscle Tone as Measured on the Modified Ashworth Scale (MAS) — -0.56; -1.21 scores on a scale — p=<0.001
Phase 3 N=258 Dysport® Adult Upper Limb Spasticity Extension Study
Nervous System Disorders
Primary: Assessment of the Long-term Safety of Dysport® Through the Collection of Treatment Emergent Adverse Events (TEAEs) — 102; 62; 47; 11 Participants
Phase 2 N=26 The Role of Trans-spinal Direct Current Stimulation (tsDCS) in Treating Patients With Hand Spasticity After Stroke
Stroke · Cerebrovascular Accident (CVA) · Hemiparesis
Primary: Mean Percent Change From Baseline in Area Under the Curve for Objectively Measured Spastic Catch Response of the Wrist Flexors at Fast Speed — 13.678; -8.783; 15.927…
N/A N=14 Targeted High-definition Transcranial Direct Current Stimulation (HD-tDCS) for Reducing Post-stroke Movement Impairments
Stroke
Primary: Fugl-Meyer Upper Extremity Assessment Part A — 4.13; 5.38; 0.88 score on a scale — p=<0.0001
N/A N=11 DDN in Stroke--COBRE
Stroke · Spasticity, Muscle · CVA
Primary: Changes in the H-reflex Amplitude in Response to Nerve Stimulation
N/A N=28 Electrical Stimulation for the Treatment of Post-Stroke Shoulder Pain
Shoulder Pain
Primary: Pain Intensity (Trial Stage) — 8.2; 6.1; 5.0; 2.1 score on a scale
Phase 3 N=148 IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Post-stroke Spasticity of the Upper Limb
Post-stroke Upper Limb Spasticity
Primary: Number of Participants With Reduction of at Least 1 Point at Week 4 Compared to Baseline in Ashworth Score in Wrist Flexors — 50; 28 Participants — p=<0.001
Phase 1 N=9 TMS and Exercise for Post-stroke Pain
Chronic Post-stroke Headache
Primary: Change in Modified Rankin Scale From Baseline to Follow-up 30 Days After Last Intervention — 0; 1 units on a scale — p=0.896
Phase 4 N=32 Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity
Stroke · Brain Injuries · Spasticity
Primary: Spastic Hypertonia as Measured by the Ashworth Scale — 2.4; 2.33; 2.36 score on a scale
Phase 4 N=220 Efficacy Of Pregabalin In Subjects With Post-Stroke Central Neuropathic Pain
Central Neuropathic Pain
Primary: Mean Pain Score at Endpoint as Measured by Daily Pain Rating Scale (DPRS) — 4.8; 5.0 scores on scale — p=0.578
N/A N=60 Assesment of Post-stroke Elbow Flexor Spasticity in Different Forearm Positions
Post-stroke Elbow Spasticity
Primary: Dynamic Component of Spasticity (Spasticity Angle) — 70; 60; 57.5 degree — p=<0.001
Phase 2 N=155 Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function
Stroke · Muscle Spasticity · Motor Neuron Disease
Primary: Change From Baseline in Forced Vital Capacity (FVC) — 2.889; 3.068; 2.923; 0.057 Liters of air
N/A N=23 Spinal Plasticity to Enhance Motor Retraining After Stroke
Stroke · Cerebrovascular Accident · Hemiparesis
Primary: Motor Control & Learning — 0.339; 0.359; 0.301 Newton
Phase 4 N=11 Assessment of Gait After Dysport Treatment
Equinovarus; Acquired
Primary: Self-Selected Velocity (SSV) — 0.41; .48; 0.48; 0.52 m/s